Nephrocare Health Services Limited (NEPHROPLUS) — Board Meeting

📢 Key Event
Board approves ESOP 2026 and Saudi subsidiary collateral support

🔄 What Changed
Approval of ESOP scheme and INR 70 Crore collateral facility for Saudi operations

🔮 What's Next
Shareholder approval required for ESOP implementation; collateral arrangement supersedes May 19 approval

💡 Investor Takeaway
The ESOPs may dilute share value, while the Saudi collateral could enhance growth but increase financial risk.

The Board approved the NephroPlus Employee Stock Option Scheme 2026, authorizing up to 20,06,814 options to purchase equity shares at a price set by the Nomination and Remuneration Committee, subject to shareholder approval and regulatory clearances. Concurrently, the Board sanctioned collateral support of up to INR 70 Crore for its Saudi subsidiary to secure funding facilities, superseding a prior May 19 approval. The ESOP aims to align employee interests with company growth, while the collateral arrangement supports expansion in Saudi Arabia.

📄 View Original Announcement (PDF)

📊 Stock Analysis — NEPHROPLUS ✨ Ask AI About This